# Phase I Study of BM2216 ER vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults

> **NCT06846567** · PHASE1 · COMPLETED · sponsor: **Zhejiang Anglikang Pharmaceutical Co., Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Diabetic Neuropathies
- Diabetes Mellitus

## Interventions

- **DRUG:** BM2216 Extended-Release tablets（5.5mg）
- **DRUG:** Mirogabalin Besilate Tablets
- **DRUG:** BM2216 Extended-Release Tablets(11mg)
- **DRUG:** BM2216 Extended-Release Tablets(16.5mg)

## Key facts

- **NCT ID:** NCT06846567
- **Lead sponsor:** Zhejiang Anglikang Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-01
- **Primary completion:** 2025-01-04
- **Final completion:** 2025-01-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846567, "Phase I Study of BM2216 ER vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06846567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*